ERBB2 and breast carcinoma: On the other hand, results of adoptive cell immunotherapies, which includes Chimeric Antigen Receptor (CAR) T cell therapy and Tumor-Infiltrating Lymphocyte (TIL) therapy, based on the isolation of antitumor T cells from the primary tumor, further ex vivo expansion and activation, and subsequent reinfusion of such cells into the patient [65], are also proving valuable in both preclinical and clinical studies for the treatment of patients with breast cancer in general and HER2 positive tumors in particular [65,103].